Comparison of antiproliferative effects of experimental and established antipsoriatic drugs on human keratinocytes, using a simple 96-well-plate assay.
Pharmacological treatments for psoriasis are generally based on antiproliferative, anti-inflammatory, or differentiation-modifying activity, or a combination of two or more of these actions. Potentially new drugs for treatment of psoriasis, which act on proliferation, can be identified by screening large compound libraries in a cell proliferation model that allows for characterization of drug effects on in vitro growth of normal human keratinocytes. High-throughput programs based on biological testing of diverse collections of compounds can rapidly identify leads for potential drug candidates in the treatment of psoriasis. In this study, we describe nonradioactive measurement of keratinocyte proliferation in the exponential growth phase in a 96-well format, using a sensitive deoxyribonucleic acid-binding dye to analyze drugs that are pharmacologically active in growth inhibition. Release of lactate dehydrogenase was used to exclude cytotoxic effects. We examined a number of compounds in a test range of 10(-7) to 10(-5) M, including known antipsoriatic drugs, and experimental drugs that are potentially useful in the treatment of psoriasis. We found strong concentration-dependent growth inhibition by dithranol, an antipsoriatic compound that is presumed to target the epidermal compartment. Methotrexate, cyclosporin A, and all-trans retinoic acid did not significantly affect proliferation at therapeutically relevant concentrations. The p38 mitogen-activated protein kinase inhibitor, SB220025, and curcumin, a natural phytochemical, inhibited keratinocyte proliferation at 10(-5) M. We conclude that this assay, in combination with the previously developed assays for psoriatic differentiation, provides a useful tool for identification of antipsoriatic drugs.
Pol
Arno
A
Department of Dermatology, University Medical Center St. Radboud, Nijmegen, The Netherlands. a.pol@derma.umcn.nl
Bergers
Mieke
M
Schalkwijk
Joost
J
D000875:Anthralin / Q000494:pharmacology / Q000627:therapeutic use; D001681:Biological Assay / Q000379:methods*; D002455:Cell Division / Q000187:drug effects*; D002478:Cells, Cultured; D003474:Curcumin / Q000494:pharmacology; D016572:Cyclosporine / Q000494:pharmacology / Q000627:therapeutic use; D004247:DNA / Q000378:metabolism; D003879:Dermatologic Agents / Q000494:pharmacology* / Q000627:therapeutic use; D004791:Enzyme Inhibitors / Q000494:pharmacology; D005456:Fluorescent Dyes / Q000378:metabolism; D006801:Humans; D015603:Keratinocytes / Q000166:cytology / Q000187:drug effects*; D008727:Methotrexate / Q000494:pharmacology / Q000627:therapeutic use; D009930:Organic Chemicals; D011419:Propidium / Q000378:metabolism; D011565:Psoriasis / Q000188:drug therapy; D014212:Tretinoin / Q000494:pharmacology / Q000627:therapeutic use
D003879:Dermatologic Agents; D004791:Enzyme Inhibitors; D005456:Fluorescent Dyes; D009930:Organic Chemicals; C099476:PicoGreen; D011419:Propidium; D014212:Tretinoin; D016572:Cyclosporine; D004247:DNA; D003474:Curcumin; D000875:Anthralin; D008727:Methotrexate